Molecular Biology Program
The Agnel Sfeir Lab
Chromosomes are the fundamental structural units of our genome. The Sfeir lab seeks to understand basic chromosome biology and how their mismanagement manifests in disease. Our research is focused on three major areas: telomere maintenance, nuclear DNA repair, and mitochondrial DNA replication and repair. A number of projects in the lab address fundamental questions related to telomere maintenance and how telomere dysfunction impacts cancer. In addition, we study an ancient yet error-prone DNA repair pathway, termed micro-homology mediated end-joining, and focus on polymerase theta, a key enzyme underlying mutagenic repair. Lastly, we investigate replication and repair of mitochondrial genomes and explore mitochondrial-nuclear crosstalk in response to mitochondrial DNA stress.
Tigano M, Vargas DC, Fu Y, Tremblay-Belzile S, and Sfeir A*. (2021) Nuclear sensing of mitochondrial DNA breaks enhances immune surveillance. Nature. Feb 24; online.
Mateos-GomezPA, GongF, NairN, MillerKM, Lazzerini-DenchiE, SfeirA*. (2015) Mammalian Polymerase Theta Promotes Alternative-NHEJ and Suppresses Recombination. Nature. Feb 12;518(7538):254-7.
Agnel Sfeir, PhD
- The Sfeir Lab investigates pathways that ensure genome fidelity and plasticity.
- PhD, UT Southwestern Medical Center, Texas (2006)
- Post-Doc, The Rockefeller University, New York (2011)
- MSc, American University of Beirut, Lebanon (2015)
- BSc, University of North Carolina, Chapel Hill, NC (2014)
- PhD, University of Pavia, Italy (2015)
- MSc, New York University, NY (2015)
- PhD, Columbia University Medical Center, NY (2018)
- PhD, University of Parma, Parma (2012)
- PhD, University of Montreal, Quebec, Canada (2018)
- Damon Runyon-Rachleff Innovator Award
- Human Frontier Science Program Young Investigator Award
- V-Foundation Scholar
- Pew-Stewart Scholar for Cancer Research
- NIH Director’s New Innovator Award
- The David and Lucile Packard Foundation Award
- Pershing Square Sohn Prize for Young Investigators
- Mallinckrodt Scholar Award
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Agnel Sfeir discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.